Curated News
By: NewsRamp Editorial Staff
May 06, 2025
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split to Maintain Nasdaq Compliance
TLDR
- TransCode Therapeutics (NASDAQ: RNAZ) implements 1-for-28 reverse stock split to raise per-share price, complying with Nasdaq's bid price requirement.
- TransCode's reverse stock split reduces outstanding common stock to about 833,620 shares post-split for efficient trading and compliance with Nasdaq's rules.
- TransCode's focus on developing RNA therapeutics to treat cancer aims to improve patient outcomes and contribute to the fight against metastatic disease.
- The 1-for-28 reverse stock split by TransCode Therapeutics is a strategic move to reshape the company's stock structure and enhance market position.
Impact - Why it Matters
This news matters as it showcases TransCode Therapeutics' strategic move to ensure compliance with Nasdaq regulations, potentially impacting investor perception and the company's stock performance. Shareholders and stakeholders should take note of this development and its implications for the company's future trajectory.
Summary
TransCode Therapeutics (NASDAQ: RNAZ) will implement a 1-for-28 reverse stock split effective May 15, 2025, to raise the per-share price and maintain Nasdaq compliance. Shares will trade on a split-adjusted basis under the existing ticker 'RNAZ'. Post-split, outstanding common stock will decrease significantly, with no fractional shares issued.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, TransCode Therapeutics Announces 1-for-28 Reverse Stock Split to Maintain Nasdaq Compliance
